Press Releases

Home / About AMP/

Press Releases


September 5, 2017
AMP Announces 2017 Award Recipients
AMP has announced the recipients of the Jeffrey A. Kant Leadership Award and the AMP Meritorious Service Award. Together with the AMP Award for Excellence in Molecular Diagnostics, these awards will be presented at the AMP 2017 Annual Meeting.
Continue Reading > >

July 14,2017
AMP to Recognize Andrew P. Feinberg, MD, MPH with 2017 Award for Excellence in Molecular Diagnostics
Epigenetics pioneer to receive Association's highest honor at upcoming Annual Meeting
Continue Reading > >


July 13, 2017
AMP Announces Results of 2017 Leadership Elections

AMP announced the results of its 2017 Leadership Elections. AMP is an organization driven by the dedication of its volunteers and looks forward to working with these newly elected leaders.

Continue Reading > >

March 22, 2017
AMP Issues Best Practice Guidelines for Next-Generation Sequencing-based Oncology Panel Validation
AMP's consensus recommendations will help clinical laboratory professionals achieve high-quality sequencing results and deliver better care for cancer patients.

Continue Reading >>

February 6, 2017
ASCP, CAP, AMP, ASCO Issue Molecular Biomarkers for the Evaluation of Colorectal Cancer Guidelines

This pivotal guideline addresses a wide range of molecular markers appropriate for testing in patients with early and advanced colorectal cancer. The guideline will aid in establishing standard molecular marker testing to help guide targeted therapy decisions, and advance personalized care for colorectal cancer patients.


Continue Reading >>




December 16, 2016

AMP Issues New Joint Guidelines to Standardize Interpretation and Reporting of Sequence Variants in Cancer


Clinical laboratory and oncology experts collaborate to publish evidence-based somatic variant classification system to improve patient care


Continue Reading >>



November 21, 2016

AMP Applauds FDA’s Decision to Delay Final Regulatory Guidance for Laboratory Developed Procedures


Organization of molecular diagnostics professionals reaffirms commitment to preserving broad access to essential patient care 


Continue Reading >>


October 19, 2016


AMP Explores New Technological Advancements to Improve Diagnosis and Optimize Treatment Selection for Invasive Infectious Diseases


AMP has announced a new report that examines how sophisticated technology advancements are being implemented to improve diagnosis and optimize treatment selection for multiple invasive, opportunistic and often deadly infectious diseases. The manuscript titled “Emerging and Future Applications of MALDI-TOF Mass Spectrometry in the Clinical Microbiology Laboratory: A Report of the Association for Molecular Pathology” has been released online ahead of publication in the November 2016 issue of The Journal of Molecular Diagnostics.


Continue Reading >>


September 26, 2016


AMP Announces 2016 Award Recipients


AMP has announced the recipients of the Jeffrey A. Kant Leadership Award and the AMP Meritorious Service Award. Together with the AMP Award for Excellence in Molecular Diagnostics, these awards will be presented at the AMP 2016 Annual Meeting.


Continue Reading>>


September 22, 2016


AMP Appreciates Opportunity to Discuss with Congressional Leaders How Laboratory Developed Procedures Benefit Patient Care


AMP recently participated in two events designed to help educate lawmakers and congressional staff about laboratory developed procedures (LDPs) and the vital role they play in precision medicine and patient care. Both the U.S. Senate Committee on Health, Education, Labor & Pensions (HELP) Hearing and the Co-hosted Congressional Briefing provided bipartisan forums for AMP leaders to discuss how LDPs are currently designed, validated, regulated, and used in a variety of clinical settings.


Continue Reading>>


September 7, 2016


AMP to Recognize Eric Lander with 2016 Award for Excellence in Molecular Diagnostics

Association's highest honor for lifetime of achievements to be presented during Annual Meeting


"As one of the true early pioneers of the human genome, Dr. Eric Lander is a well-deserved recipient of the AMP Award for Excellence in Molecular Diagnostics," said Charles E. Hill, MD, PhD, AMP President.. "Throughout his career, Dr. Lander and his colleagues have developed tools and applied methods that have transformed our understanding of the molecular basis of rare and common genetic diseases, including cancer. His seminal publications, fundamental discoveries, and significant scientific contributions have had a massive impact on human health by providing us with the framework for the modern practice of clinical molecular diagnostics."


Continue Reading>>


August 17, 2016


AMP Establishes New Standard for Clinical Utility of Molecular Diagnostics for Inherited Diseases and Cancer


New JMD report recognizes value of testing procedures and promotes paradigm corrections to drive widespread adoption of a more proactive, patient-centered approach to modern healthcare


“Molecular pathology testing procedures are vital tools for insight and analysis into various aspects of clinical practice,” said Roger D. Klein, MD, JD, AMP Professional Relations Chair. “However, we need a more practical and patient-centered approach for evaluating clinical usefulness before we can truly deliver the promise of precision medicine.”


Continue Reading>>



April 13, 2016


AMP Releases Results from 2015 Genomic Sequencing Procedure Microcosting and Health Economic Cost-Impact Analyses


New publication in The Journal of Molecular Diagnostics describes cost and value analysis of gene panels including non-small cell lung cancer, exome sequencing, and hearing loss gene panels


"Genomic Sequencing Procedures are changing the way clinicians are diagnosing and managing hereditary diseases and the delivery of oncology care," said Linda Sabatini, PhD, HCLD, First Author and Project Leader, Director of Molecular Diagnostics at NorthShore University HealthSystem. "We hope that laboratories will use these tools to assess their individual costs, to consider the value structure in their own patient populations, and to contribute their data to the ongoing dialogue regarding the impact of GSPs on improving patient care."


Continue Reading>>


March 14, 2016


AMP Issues Statement Regarding FDA Letters to Two Texas Hospitals about Rapid Detection Zika Test

AMP is very concerned and disappointed to see the FDA taking enforcement action against the physicians at Texas Children's Hospital and Houston Methodist Hospital for their laboratory developed procedure (LDP) for Zika virus, which was designed to identify virus-specific RNA sequences in a large metropolitan area. Given the ongoing outbreak of the infection and risk of infection in the Houston area, these types of tests are critical for patient care and should be made available to these patients in need.


Continue Reading>>


February 5, 2016


AMP Updates Pathology Residency Curriculum Recommendations


New report published in The Journal of Molecular Diagnostics focuses on improving pathology training programs for molecular pathology and genomic medicine


The AMP paper provides residency programs with specific recommendations from subject matter experts on 10 major molecular pathology topics: basic molecular pathology goals and laboratory management; basic concepts in molecular biology and genetics; technology; inherited disorders; oncology; infectious diseases; pharmacogenetics; histocompatibility and identity; genomics, and information management.


Continue Reading>>



December 16, 2015


AMP Responds to FDA Report on Oversight of Laboratory Developed Testing Procedures


AMP analysis concludes report grossly misrepresents the public health concerns of laboratory developed testing procedures


AMP has responds to FDA's recently released report titled "The Public Health Evidence for FDA Oversight of Laboratory Developed Tests: 20 Case Studies" with a detailed analysis of the laboratory developed procedures (LDPs) mentioned in the FDA report. After a careful and thorough examination of the LDPs mentioned in FDA's report, AMP concluded that FDA oversight would likely prevent few of the potential patient harms postulated by the Agency. Rather the Centers for Medicare & Medicare Services (CMS), which has statutory authority through the CLIA program, would have been more successful than FDA at addressing these potential problems.


Continue Reading>>




AMP Submits Written Testimony for Hearing on "Examining the Regulation of Diagnostic Tests and Laboratory Operations"

>>Download the Entire Press Release



AMP Hosts Symposium on Coding, Coverage, and Reimbursement of Molecular Diagnostic Tests

>>Download the Entire Press Release



Congressman Michael Burgess, MD, Speaks at Session on CLIA Modernization

>>Download the Entire Press Release



AMP Announces 2015 Award Winners

>>Download the Entire Press Release



AMP Publishes article on NGS for Diagnostics and Management of Infectious Diseases

>>Download the Entire Press Release



AMP Meets with Senate HELP Committee to propose CLIA Modernization

>>Download the Entire Press Release



AMP Publishes its Vision for the Role of the Laboratory Professional in the Era of Genomic Medicine

>>Download the Entire Press Release



AMP Launches International Affairs Committee

>>Download the Entire Press Release



AMP Publishes Compilation of Current Research on Liquid Biopsy in May issue of The Journal of Molecular Diagnostics

>>Download the Entire Press Release



ASCP, CAP, AMP, and ASCO Issue Draft Colorectal Cancer Molecular Marker Testing Guideline and Announce Opening of Public Comment Period

>>Download the Entire Press Release



AMP Submits Written Comments to FDA on Regulation of NGS Diagnostic Tests

>>Download the Entire Press Release



AMP Releases Cost Analysis Results and Health Economic Evaluation Models for Several Genomic Sequencing Procedure Codes

>>Download the Entire Press Release



AMP Recommends FDA Focus on Evaluating and Ensuring Consistent Performance of Next Generation Sequencing Diagnostic Tests

>>Download the Entire Press Release



AMP Publishes Article in JMD presenting the Laboratory Perspective of Incidental Findings Reporting

>>Download the Entire Press Release



AMP and CAP Formalize Collaboration to Advance Molecular and General Pathology

>>Download the Entire Press Release



AMP Supports DTC Tests when Information is Actionable by Patients

>>Download the Entire Press Release



AMP Submits Written Comments to FDA on Proposed Regulation of LDTs

>>Download the Entire Press Release



Revisions to Molecular Testing Guidelines Continues to Give Hope to Lung Cancer Patients

>>Download the Entire Press Release



AMP Releases "Molecular Diagnostic Perfect Storm" Paper Addressing the Convergence of Regulatory and Reimbursement Forces that Threaten Patient Care

>>Download the Entire Press Release



AMP has Strong Presence at FDA Workshop on LDTs, Delivers Message of Optimizing Patient Care through Molecular Diagnostics

>>Download the Entire Press Release





AMP 2014 Annual Meeting Wraps-up with Record Level Attendance

>>Download the Entire Press Release



AMP Announces Award Winners

>>Download the Entire Press Release



AMP Establishes Informatics Subdivision

>>Download the Entire Press Release



AMP Adds Late-Breaking Session on LDPs Oversight and Regulation

>>Download the Entire Press Release



AMP Voices Concern with U.S. FDA Anticipated Details of Laboratory Developed Test Draft Guidance

>>Download the Entire Press Release



Francis S. Collins, MD, PhD, to Speak at AMP 2014 Annual Meeting

>>Download the Entire Press Release



AMP Celebrates the Contributions of Medical Laboratory Professionals during Lab Week 2014

>>Download the Entire Press Release



AMP Publishes Curriculum Recommendations for Medical Laboratory Scientists

>>Download the Entire Press Release




AMP Releases White Paper on LDTs - Coins New Term

>>Download Entire Press Release



AMP Announces Annual Meeting Highlights

>>Download Entire Press Release


AMP Announces Award Recipients for 2013

>>Download Entire Press Release


AMP Joins the Federation of American Societies for Experimental Biology

>>Download Entire Press Release


AMP Celebrates U.S. Supreme Court Decision on AMP v Myriad

>>Download Entire Press Release

Professional Societies Delineate Concerns, Offer Recommendations Regarding Interim Pricing for Molecular Tests
>>More Information

CAP / IASLC / AMP Release Lung Biomarker Guideline
Advances in Molecular Testing Offer New Hope for Lung Cancer Patients
>>Download Entire Press Release


AMP Releases Proposal Addressing CPT Coding for GSAs

Report to AMA documents the challenges, related technology, and proposed coding scheme for GSAs

>>Download Entire Press Release



AMP Publishes Report on NGS

Report provides overview of possibilities, challenges, and applications of next-generation sequencing

>>Download Entire Press Release


AMP Appeals Breast Cancer Gene Patent Case to U.S. Supreme Court
Case Challenges Patents as Dangerous Roadblock to Patient Care, Medical Innovation

>>Download Entire Press Release


AMP Receives 40% Increase in Abstract Submissions

The record-breaking number of abstract submissions for the AMP 2012 Annual Meeting on Genomic Medicine is consistent with the increased number of exhibiting companies and anticipated number of attendees.

>>Download Entire Press Release

AMP Developing a CPT Coding Proposal for Next Generation Sequencing

Proposal to be completed by the end of June and released for feedback from stakeholders in the laboratory and payer community before submission of a formal proposal to the AMA CPT Editorial Panel.
>>Download Entire Press Release

AMP Forms Working Group to Further Consider Oversight of Lab Tests

The goal of the group is to produce a white paper that will outline the key issues, and provide AMP's recommendations for future LDT oversight.
>>Download Entire Press Release

AMP Optimistic in Suit to invalidate Patents on Breast Cancer Genes
AMP is optimistic that it will ultimately prevail in its lawsuit to invalidate patents on two genes that are known to cause breast cancer. >>Download Entire Press Release

AMP Applauds Supreme Court Ruling: Sees Win for Patients and Personalized Medicine
AMP is encouraged by the Court's recognition that Prometheus patents neither promote the advancement of medical practice, nor benefit patient care.
>>Download Entire Press Release

AMP Requests Moratorium on Human Gene Patenting
AMP testified at the U.S. Patent and Trademark Office hearing regarding patents on human genes.
>>Download Entire Press Release

New Governance Structure Approved by AMP Membership
AMP adopts change in governance structure as part of newly implemented strategic plan.
>>Download Entire Press Release


U.S. Supreme Court Petitioned to Review AMP, et al. Lawsuit on Gene Patents
AMP is optimistic the Supreme Court will follow its precedents that render natural products, natural laws, and natural phenomena ineligible for patent protection.
>>Download Entire Press Release

AMP Responds to NIH Proteomics Patent
AMP responded to the NIH Proteomics Patent, opposing their proposal to exclusively license the subject matter of a cancer-related proteonomics patent application filed by the Agency.
>>Download Entire Press Release

AMP Comments on Proposed Changes to the Common Rule
AMP submitted comments to the DHHS calling for language that identifies biospecimen activities to be part of clinical care and the practice of medicine...
>>Download Entire Press Release

AMP Comments to FDA Companion Dx Draft Guidelines
AMP submitted comments to the FDA regarding the FDA’s “Draft Guidance for Industry and Food and Drug Administration Staff - In Vitro Companion Diagnostic Devices”.
>>Download Entire Press Release

AMP Comments to NIH about proposed GTR
AMP voiced concerns about the proposed Genetic Testing Rregistry (GTR) as currently designed. Requested that NIH take clarity and cost into consideration.
>>Download Entire Press Release

AMP Announces 2011 Annual Meeting Program
AMP announced the program of events for its Annual Meeting, being held November 17-19 at the Gaylord Texan Hotel and Convention Center in Grapevine, Texas.
>>Download Entire Press Release

AMP Responds to FDA RUO/IUO FAQ's
AMP submitted comments to the FDA on the draft guidance document titled, “Commercially Distributed In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only: Frequently Asked Questions.”
>>Download Entire Press Release

AMP Appoints Mary Steele Williams to Position of Executive Director
AMP appointed Mary Steele Williams, MNA, MT(ASCP)SM to the position of Executive Director. This move is indicative of the tremendous growth experienced by the 17 year-old Association. The outgoing Executive Officer, Mark E. Sobel, MD, PhD, a founding member and past President, served for ten years as AMP’s part time Executive Officer and steered it to its current prominence as the voice of molecular pathology.
>>Download Entire Press Release

AMP Comments at FDA Meeting on Next Generation Sequencing
On behalf of AMP, Dr. Elaine Lyon gave public comments at the US Food and Drug Administration's (FDA) meeting on "Ultra High Throughput Sequencing for Clinical Diagnostic Applications - Approaches to Assess Analytical Validity." As they begin developing their program to evaluate sequencing based diagnostics, AMP advised FDA officials on many important considerations for evaluating analytical validity.
>>Download Entire Press Release

AMP Releases Statement on Diagnostics in Drug Labels
AMP released its new position statement on reference to diagnostic tests in drug labels. AMP's statement outlines the organization's commitment to providing high quality medical care and ensuring patients have access to the most appropriate diagnostic tests based on their clinical presentation.
>>Download Entire Press Release



AMP Responds to Genetic Test Registry Request for Information
Bethesda, MD (July 29, 2010): Today, the Association for Molecular Pathology (AMP) submitted written comments in response to the Request for Information made by the National Institutes of Health (NIH) for its Genetic Test Registry (GTR). AMP conducted a survey of its membership to formulate a comprehensive response to the RFI.
>>Download Entire Press Release

AMP Presents at FDA Meeting on Regulating Diagnostics
College Park, MD (July 20, 2010): The Association for Molecular Pathology (AMP) participated in the Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) public meeting on the oversight of laboratory developed tests (LDTs). Dr. Karen Mann, President of AMP, served on the second panel of the meeting titled, Clinical Laboratory Challenges. Additionally, Dr. Elaine Lyon, Chair of the AMP Professional Relations Committee, presented public comments.
>>Download Entire Press Release

AMP Comments at FDA Meeting on Array-Based Tests
Bethesda, MD (June 30, 2010): Today, the Association for Molecular Pathology (AMP) presented comments at the US Food & Drug Administration’s public meeting on array-based cytogenetic tests. The FDA convened the meeting to seek answers to more than a dozen questions they had on how to evaluate the performance, interpret results and report findings of array-based cytogenetic tests for copy number variation (CNV).
>>Download Entire Press Release

AMP Submits Comments on SACGHS Report
Washington, DC (June 29, 2010): Today, the Association for Molecular Pathology (AMP) submitted comments on the Draft Report of the Secretary's Advisory Committee on Genetics, Health, and Society on Genetics Education and Training of Health Care Professionals, Public Health Providers, and Consumers.
>>Download Entire Press Release


AMP Asks FDA to Address Berriers to Device Innovation
Washington, DC (June 25, 2010): Yesterday, the Association for Molecular Pathology (AMP) gave public comments at the FDA's Center for Devices and Radiological Health (CDRH) Council meeting on Medical Device Innovation: Barriers to Market for Molecular Diagnostic
>>Download Entire Press Release

AMP Commends SACGHS Whole Genome Sequencing Focus, Raises Ethical Questions and Forms Working Group on Whole Genome Analysis
Today, the Association for Molecular Pathology (AMP) presented public comments to the Secretary's Advisory Committee on Genetics, Health and Society (SACHGS) meeting focused on whole genome sequencing. In anticipation of advances in sequencing and its incorporation into clinical practice, AMP raised ethical and laboratory practice concerns for the Committee's consideration.
>>Download Entire Press Release

AMP Cautions Consumers About Direct Access Genetic Testing
In response to recent announcements about consumer genetic tests being made available in retail drugstores, the AMP today reiterated its position that these tests should be provided to the public only through the services of appropriate health care professionals that order tests from CLIA-certified laboratories.
>>Download Entire Press Release


The Association for Molecular Pathology Celebrates Ruling in DNA Patent Case
The Association for Molecular Pathology (AMP) applauds US District Judge Robert Sweet's ruling in favor of the plaintiffs in the lawsuit, Association for Molecular Pathology, et al. v. U.S. Patent and Trademark Office, et al. "This is a landmark decision that has the potential to dramatically improve patient access to genetic testing. It is a boon to personalized medicine in the purest sense as nothing is more personal than one's genetic makeup. This judgment removes numerous barriers and impediments to clinical research, testing, and innovation since patented genes cannot be invented around, and has implications for how we evaluate each and every patient's genetic information" said Dr. Karen Mann, AMP President.
>>Download Entire Press Release


AMP Applauds SACGHS on Release of Final Report on DNA Patents
The Association for Molecular Pathology (AMP) commends the Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS) for its thoughtful, deliberative exploration into the challenges of gene patents and is hopeful that the Secretary of the Department of Health and Human Services will act swiftly to adopt measures that would protect patients from the harms of gene patents and exclusive licensing practices.
>>Download Entire Press Release


AMP Releases Statement on Oversight of Laboratory Tests
The Association for Molecular Pathology releases a position statement on the oversight of laboratory developed tests to foster discussion among stakeholders and meets wit the Food & Drug Administration.
>>Download Entire Press Release



MEDIA ALERT:  Association for Molecular Pathology's 15th Annual Meeting and Exhibits
The Association for Molecular Pathology (AMP) invites the media to follow its upcoming 2009 Annual Meeting and Exhibits and learn about the latest advances in clinical molecular diagnostics.
>>Download Entire Press Release



Association for Molecular Pathology Commends SACGHS on their DNA Patent Report

The Association for Molecular Pathology (AMP) provided comments at the Secretary's Advisory Committee on Genetics, Health and Society (SACGHS) meeting on Oct. 8.  AMP opposes the patenting of all naturally occurring genetic material and has signed on as a lead plaintiff in the ACLU case challenging Myriad Genetics' patents on the BRCA 1 and BRCA 2 genes.  AMP thanked SACGHS for studying how both patents and restrictive licensing limit patient access and potentially reduce the quality of tests.

>>Download Entire Press Release



Association for Molecular Pathology Outlines Key Principles for Health Care Reform

The Association for Molecular Pathology today announced a set of key principles to guide the organization's public policy advocacy amid current effort in Congress and the Obama administration to reform the nation's health care system. These core principles specifically address the practice of clinical laboratory medicine and the use of molecular-based diagnostic tests.

>>Download Entire Press Release



Association for Molecular Pathology Urges Comprehensive Measures to Incorporate Molecular Diagnostic Tests Into Comparative Effectiveness Research
The Association for Molecular Pathology (AMP) today released the text of a comment letter it has provided to the Federal Coordinating Council for Comparative Effectiveness Research (CER) in which AMP sets forth its recommendations for priority areas on which to focus CER activities.
>>Download Entire Press Release


Association for Molecular Pathology Comments to the SACGHS
In pubic comments given today before the Secretary of Health and Human Services Advisory Committee on Genetics, Health and Society (SACGHS), the Association for Molecular Pathology (AMP) addressed three areas: Comparative Effectiveness Research (CER), evidence for coverage of genetic and genomic tests, and gene patents.
>>Download Entire Press Release


Association for Molecular Pathology Urges Secretary's Advisory Committee to Give Greater Consideration to the Negative Impact of Gene Patents and Restrictive Licensing Practices on Public Health
AMP Comments on Draft Report on Gene Patents and Licensing by the Secretary's Advisory Committee on Genetics, Health and Society
Washington, DC - May 21, 2009 - The Association for Molecular Pathology today urged the Secretary of Health and Human Services' Advisory Committee on Genetics, Health and Society to more definitively explore the negative impact on public health that derives from gene patents and from exclusive and restrictive licensing practices as part of its draft report, Gene Patents and Licensing and Their Impact on Patient Access to Genetic Tests.
>>Download Entire Press Release


Association for Molecular Pathology Joins the American Civil Liberties Union to Challenge the Constitutionality of Gene Patents
Washington, DC - May 13, 2009 - The Association for Molecular Pathology (AMP) announced today that it is working with the American Civil Liberties Union (ACLU) and the Public Patent Foundation to bring a lawsuit charging that patents on two human genes associated with breast and ovarian cancer are unconstitutional and should be invalidated. Individuals with certain mutations long these two genes, known as BRCA1 and BRCA2, are at a significantly higher risk for developing hereditary breast and ovarian cancers.
>>Download Entire Press Release


The Association for Molecular Pathology calls for enhanced communication and collaboration between state and local public health laboratories and molecular pathology laboratories to combat the swine influenza A (H1N1) outbreak
Bethesda, MD - April 30, 2009 -- As the nation faces the ongoing public health challenges of a new circulating strain of influenza, the Association for Molecular Pathology (AMP) encourages close collaboration between molecular diagnostics laboratories, CDC , and public health laboratories to ensure prompt diagnosis and timely surveillance of the outbreak. AMP's members are physicians, doctoral scientists and medical technologists with expertise in developing, validating and providing laboratory tests based on molecular methods. They have the education and training to offer high quality molecular diagnostic testing for influenza and extensive experience providing clinical testing for seasonal influenza.
>>Download Entire Press Release


Association of Molecular Pathology Urges an End to the Practice of Granting Patents on Single Genes and Gene Sequences in the Human Genome and to Exclusive Licenses to Genetic Discoveries
In newly adopted Position Statement, group also calls for stakeholders to develop more innovative models of intellectual property to encourage innovation and improve patient access to improved molecular tests
WASHINGTON, DC - December 1, 2008 - In a statement delivered today before the Secretary of Health and Human Services' Advisory Committee of Genetics, Health and Society (SACGHS), the Association of Molecular Pathology (AMP) urged an end to the practice of granting patents on single genes, sequences of the genome or correlations between genetic variations and biological states. AMP also encouraged groups that currently hold gene patents, including higher educational and research institutions, not to grant exclusive licenses to access these patents...
>>Download Entire Press Release

Association for Molecular Pathology holds 14th Annual Meeting and Exhibits, October 29 - November 2, 2008 in Grapevine, TX
Bethesda, MD - October 27, 2008 - The Association for Molecular Pathology (AMP) 14th Annual Meeting and Exhibits will be held October 29 - November 2, 2008 at the Gaylord Texan Resort and Convention Center in Grapevine, Texas. This meeting will feature three days of plenary sessions and workshops in hematopathology, infectious diseases, inherited genetic diseases, solid tumors, and current technical topics presented by leading scientists and diagnosticians in the field of molecular diagnostics...
>>Download Entire Press Release

Association for Molecular Pathology to Increase Public Policy Advocacy Role
Organization Retains HealthFutures as Government Relations Consultant

BETHESDA, MD - July 1, 2008 -- The Association for Molecular Pathology (AMP) announced today plans to significantly increase its activity and visibility in the federal public policy arena for 2008 and beyond. In response to a range of new issues that will impact the emerging field of molecular diagnostics, and in preparation for a national dialogue on health care reform likely to take place in the next presidential administration, the organization will be more actively engaged with policy makers in Congress and the Executive Branch on legislative, regulatory and policy matters...
>>Download Entire Press Release


Daniel H. Farkas, Ph.D. to Receive 2007 Leadership Award From Association for Molecular Pathology
Grand Rapids, Mich. April 3, 2007 - The Center for Molecular Medicine (CMM) today announced that Executive Director Daniel H. Farkas, Ph.D., has been named the recipient of the 2007 Leadership Award from the Association for Molecular Pathology (AMP).
The AMP was founded in 1995 to provide structure and leadership to the then-emerging field of diagnostic molecular pathology. Since 2005, the organization has honored an AMP member with its Leadership Award, based on that member's accomplishments and notable contributions to the vision and direction of both AMP and the field of diagnostic molecular pathology...
 >>Download Entire Press Release